[1]
|
Rowley, A.H. and Shulman, S.T. (2010) Pathogenesis and Management of Kawasaki Disease. Expert Review of Anti-Infective Therapy, 8, 197-203.
https://doi.org/10.1586/eri.09.109
|
[2]
|
Kawasaki, T. and Naoe, S. (2014) History of Kawasaki Disease. Clinical and Experimental Nephrology, 18, 301-304. https://doi.org/10.1007/s10157-013-0877-6
|
[3]
|
Chang, C.L., Wong, C.S., Yang, Y.C. and Chiu, N.C. (2018) Influence of Latitude on the Prevalence of Kawasaki Disease: A Retrospective Cohort Study from the Taiwan National Health Insurance Database and Review of the Literature. International Journal of Environmental Research and Public Health, 15, 845.
https://doi.org/10.3390/ijerph15050845
|
[4]
|
Ayusawa, M., Sonobe, T., Uemura, S., Ogawa, S., Nakamura, Y., et al. (2005) Revision of Diagnostic Guidelines for Kawasaki Disease (the 5th Revised Edition). Pediatrics International: Official Journal of the Japan Pediatric Society, 47, 232-234.
https://doi.org/10.1111/j.1442-200x.2005.02033.x
|
[5]
|
McCrindle, B.W., Rowley, A.H., Newburger, J.W., Burns, J.C., Bolger, A.F., et al. (2017) Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation, 135, e927-e999. https://doi.org/10.1161/CIR.0000000000000484
|
[6]
|
Esper, F., Shapiro, E.D., Weibel, C., Ferguson, D., Landry, M.L. and Kahn, J.S. (2005) Association between a Novel Human Coronavirus and Kawasaki Disease. The Journal of Infectious Diseases, 191, 499-502. https://doi.org/10.1086/428291
|
[7]
|
Khor, C.C., Davila, S., Breunis, W.B., Lee, Y.C., Shimizu, C., et al. (2011) Genome-Wide Association Study Identifies FCGR2A as a Susceptibility Locus for Kawasaki Disease. Nature Genetics, 43 1241-1246. https://doi.org/10.1038/ng.981
|
[8]
|
Khor, C.C., Davila, S., Shimizu, C., Sheng, S., Matsubara, T., et al. (2011) Genome-Wide Linkage and Association Mapping Identify Susceptibility Alleles in ABCC4 for Kawasaki Disease. Journal of Medical Genetics, 48, 467-472.
https://doi.org/10.1136/jmg.2010.086611
|
[9]
|
Meissner, H.C. and Leung, D.Y. (2000) Superantigens, Conventional Antigens and the Etiology of Kawasaki Syndrome. The Pediatric Infectious Disease Journal, 19, 91-94. https://doi.org/10.1097/00006454-200002000-00001
|
[10]
|
Yeung, R.S. (2010) Kawasaki Disease: Update on Pathogenesis. Current Opinion in Rheumatology, 22 551-560. https://doi.org/10.1097/BOR.0b013e32833cf051
|
[11]
|
Animasahun, B.O., Adekunle, M., Kushimo, O. and Fadipe, C. (2017) The Diagnosis of Kawasaki Disease among Nigerian Children: A Nightmare for the Caregivers and the Doctors. Journal of Public Health and Emergency, 1, 69.
https://doi.org/10.21037/jphe.2017.06.06
|
[12]
|
Gonzalez-Mata, A., Ulloa-Gutierrez, R., Brea, J., Soza, G. and Tremoulet, A.H. (2014) Origin and Importance of the Latin American Kawasaki Disease Network (REKAMLATINA). Revista Chilena de Infectologia, 31, 330-332.
https://doi.org/10.4067/S0716-10182014000300012
|
[13]
|
Sano, T., Makino, N., Aoyama, Y., Ae, R., Kojo, T., Kotani, K., Nakamura, Y. and Yanagawa, H. (2016) Temporal and Geographical Clustering of Kawasaki Disease in Japan: 2007-2012. Pediatrics International: Official Journal of the Japan Pediatric Society, 58, 1140-1145. https://doi.org/10.1111/ped.12970
|
[14]
|
Kim, G.B., Park, S., Eun, L.Y., Han, J.W., Lee, S.Y., et al. (2017) Epidemiology and Clinical Features of Kawasaki Disease in South Korea, 2012-2014. The Pediatric Infectious Disease Journal, 36, 482-485.
https://doi.org/10.1097/INF.0000000000001474
|
[15]
|
Huang, Y.-H., Lin, K.-M., Ho, S.-C., Yan, J.-H., Lo, M.-H. and Kuo, H.-C. (2019) Increased Incidence of Kawasaki Disease in Taiwan in Recent Years: A 15 Years Nationwide Population-Based Cohort Study. Frontiers in Pediatrics, 7, 121.
https://doi.org/10.3389/fped.2019.00121
|
[16]
|
Du, Z.D., Zhao, D., Du, J., Zhang, Y.L., Lin, Y., Liu, C. and Zhang, T. (2007) Epidemiologic Study on Kawasaki Disease in Beijing from 2000 through 2004. The Pediatric Infectious Disease Journal, 26, 449-451.
https://doi.org/10.1097/01.inf.0000261196.79223.18
|
[17]
|
Ng, Y.M., Sung, R.Y., So, L.Y., Fong, N.C., Ho, M.H., Cheng, Y.W., Lee, S.H., Mak, W.C., Wong, D.M., Yam, M.C., et al. (2005) Kawasaki Disease in Hong Kong, 1994 to 2000. Hong Kong Medical Journal, 11, 331-335.
|
[18]
|
Cheung, Y.F. (2012) Kawasaki Disease in Hong Kong 2000-2011. 10th International Kawasaki Disease Symposium: From Genetics to Clinics, Kyoto, 7-10 February 2012, 42-43. http://www.blackwellpublishing.com/journals/PED
|
[19]
|
Holman, R.C., Belay, E.D., Christensen, K.Y., Folkema, A.M., Steiner, C.A. and Schonberger, L.B. (2010) Hospitalizations for Kawasaki Syndrome among Children in the United States, 1997-2007. The Pediatric Infectious Disease Journal, 29, 483-488. https://doi.org/10.1097/INF.0b013e3181cf8705
|
[20]
|
Lynch, M., Holman, R.C., Mulligan, A., Belay, E.D. and Schonberger, L.B. (2003) Kawasaki Syndrome Hospitalizations in Ireland, 1996 through 2000. The Pediatric Infectious Disease Journal, 22, 959-963.
https://doi.org/10.1097/01.inf.0000095194.83814.ee
|
[21]
|
Saundankar, J., Yim, D., Itotoh, B., Payne, R., Maslin, K., et al. (2014) The Epidemiology and Clinical Features of Kawasaki Disease in Australia. Pediatrics, 133, e1009.
https://doi.org/10.1542/peds.2013-2936
|
[22]
|
Heaton, P., Wilson, N., Nicholson, R., Doran, J., Parsons, A. and Aiken, G. (2006) Kawasaki Disease in New Zealand. Journal of Paediatrics and Child Health, 42, 184-190. https://doi.org/10.1111/j.1440-1754.2006.00827.x
|
[23]
|
Uehara, R. and Belay, E.D. (2012) Epidemiology of Kawasaki Disease in Asia, Europe, and the United States. Journal of Epidemiology, 22, 79-85.
https://doi.org/10.2188/jea.JE20110131
|
[24]
|
Lee, H. and Shin, J. (2017) Myocardial Assessment in School-Aged Children with Past Kawasaki Disease. Journal of Korean Medical Science, 32, 1835-1839.
https://doi.org/10.3346/jkms.2017.32.11.1835
|
[25]
|
Song, R., Yao, W. and Li, X. (2017) Efficacy of Four Scoring Systems in Predicting Intravenous Immunoglobulin Resistance in Children with Kawasaki Disease in a Children’s Hospital in Beijing, North China. The Journal of Pediatrics, 184, 120-124. https://doi.org/10.1016/j.jpeds.2016.12.018
|
[26]
|
Rigante, D., Andreozzi, L., Fastiggi, M., Bracci, B., Natale, M.F. and Esposito, S. (2016) Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome. International Journal of Molecular Sciences. 17, 278-278.
https://doi.org/10.3390/ijms17030278
|
[27]
|
Xue, L.J., Wu, R., Du, G.L., Xu, Y., Yuan, K.Y., et al. (2017) Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: A Meta-Analysis. Clinical Reviews in Allergy & Immunology, 52, 389-400.
https://doi.org/10.1007/s12016-016-8581-4
|
[28]
|
Son, M.B., Gauvreau, K., Ma, L., Baker, A.L., Sundel, R.P., et al. (2009) Treatment of Kawasaki Disease: Analysis of 27 US Pediatric Hospitals from 2001 to 2006. Pediatrics, 124, 1-8. https://doi.org/10.1542/peds.2008-0730
|
[29]
|
Furukawa, T., Kishiro, M., Akimoto, K., Nagata, S., Shimizu, T. and Yamashiro, Y. (2008) Effects of Steroid Pulse Therapy on Immunoglobulin-Resistant Kawasaki Disease. Archives of Disease in Childhood, 93, 142-146.
https://doi.org/10.1136/adc.2007.126144
|
[30]
|
Sonoda, K., Mori, M., Hokosaki, T. and Yokota, S. (2014) Infliximab plus Plasma Exchange Rescue Therapy in Kawasaki Disease. The Journal of Pediatrics, 164, 1128-1132.e1. https://doi.org/10.1016/j.jpeds.2014.01.020
|
[31]
|
Portman, M.A., et al. (2019) Etanercept with IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial. Pediatrics, 143, e20183675.
https://doi.org/10.1542/peds.2018-3675
|
[32]
|
Burns, J.C., Kone-Paut, I., Kuijpers, T., Shimizu, C., Tremoulet, A. and Arditi, M. (2017) Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease. Arthritis & Rheumatology (Hoboken, NJ), 69, 268-276. https://doi.org/10.1002/art.39975
|
[33]
|
Dusser, P. and Kone-Paut, I. (2017) IL-1 Inhibition May Have an Important Role in Treating Refractory Kawasaki Disease. Frontiers in Pharmacology, 8, 163.
https://doi.org/10.3389/fphar.2017.00163
|
[34]
|
Newburger, J.W., Takahashi, M., Gerber, M.A., Gewitz, M.H., Tani, L.Y., et al. (2004) Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation, 110, 2747-2771.
https://doi.org/10.1161/01.CIR.0000145143.19711.78
|
[35]
|
Kaida, Y., Kambe, T., Kishimoto, S., Koteda, Y., Suda, K., et al. (2017) Efficacy and Safety of Plasma Exchange for Kawasaki Disease with Coronary Artery Dilatation. Renal Replacement Therapy, 3, 50. https://doi.org/10.1186/s41100-017-0130-y
|
[36]
|
Noguchi, S., Saito, J., Kudo, T., Hashiba, E. and Hirota, K. (2018) Safety and Efficacy of Plasma Exchange Therapy for Kawasaki Disease in Children in Intensive Care Unit: Case Series. JA Clinical Reports, 4, 25.
https://doi.org/10.1186/s40981-018-0156-3
|
[37]
|
Wallace, C.A., French, J.W., Kahn, S.J. and Sherry, D.D. (2000) Initial Intravenous Gammaglobulin Treatment Failure in Kawasaki Disease. Pediatrics, 105, E78.
https://doi.org/10.1542/peds.105.6.e78
|
[38]
|
Suzuki, H., Terai, M., Hamada, H., Honda, T., Suenaga, T., et al. (2011) Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin. The Pediatric Infectious Disease Journal, 30, 871-876.
https://doi.org/10.1097/INF.0b013e318220c3cf
|
[39]
|
Jang, H., Kim, K.Y. and Kim, D.S. (2018) Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for Intravenous Immunoglobulin-Resistant Kawasaki Disease. Yonsei Medical Journal, 59, 113-118.
https://doi.org/10.3349/ymj.2018.59.1.113
|